Acadian Asset Management
TCRR

Acadian Asset Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Acadian Asset Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-812,459
Closed -$1.22M – 1966
2023
Q1 		$1.22M Sell
812,459
-62,394
-7% -$84K 0.01% 830
2022
Q4 		$872K Buy
874,853
+191,739
+28% +$258K ﹤0.01% 882
2022
Q3 		$1.23M Buy
683,114
+141,239
+26% +$410K 0.01% 752
2022
Q2 		$1.57M Buy
541,875
+62,357
+13% +$154K 0.01% 690
2022
Q1 		$1.32M Buy
479,518
+465,207
+3,251% +$1.46M 0.01% 771
2021
Q4 		$65K Buy
+14,311
New +$89.5K ﹤0.01% 1453
2020
Q2 		– Sell
-1,766
Closed -$14K – 2379
2020
Q1 		$14K Buy
+1,766
New +$21.6K ﹤0.01% 1689

Acadian Asset Management's TCRR Position: Q2 2023 in Review

Acadian Asset Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 812,459 shares — an estimated $1.22M sold.

Acadian Asset Management first reported a position in TCRR in Q1 2020 and held it in 7 quarters. The position peaked at $1.57M in Q2 2022. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Acadian Asset Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Acadian Asset Management sold 812,459 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.22M.
  • Acadian Asset Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • Acadian Asset Management's TCR2 Therapeutics Inc. Common Stock position peaked at $1.57M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.